Unichem Laboratories quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	633	527	+20.1%
EBITDA	69.9	22.5	+211.0%
EBITDA margin	11.1%	4.3%	+6.8 pts
Profit before tax	49.0	−9.0	—
Net profit	41.5	−10.5	—
EPS	₹6.61	−₹1.49	—

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	633	575	521	579	527	587	533	462	446	432	434	416	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	15.6	23.5	11.8	21.0	6.8	9.3	13.6	8.8	3.9	6.2	11.3	5.5
	648	599	533	600	533	596	547	471	450	438	446	421
	190	184	174	193	217	275	175	210	208	198	194	175
	67.3	91.8	48.9	39.8	51.0	33.5	63.4	15.2	0.3	0.2	0.2	0.2
	31.3	−7.8	13.9	37.6	−23.4	−44.2	−47.0	−51.0	−47.8	−31.0	−27.6	−12.4
	103	92.9	99.3	100	107	96.5	102	98.8	98.5	99.4	98.1	96.7
	6.6	9.4	7.4	8.2	6.5	5.5	6.8	4.8	4.0	4.6	5.6	6.7
	29.9	30.6	31.3	31.5	31.8	29.7	30.5	28.5	28.3	27.2	27.9	29.5
	171	167	140	142	152	142	154	131	144	140	132	147
	599	567	515	552	542	539	485	438	435	438	430	443
	69.9	47.7	44.8	66.2	22.5	83.7	85.5	57.5	43.5	25.4	38.1	8.8
	40.0	17.1	13.5	34.7	−9.3	54.0	55.0	29.0	15.2	−1.8	10.3	−20.7
Profit
	49.0	31.2	17.9	47.4	−9.0	57.8	61.9	33.0	15.0	−0.2	16.0	−21.9
	0.0	−12.4	276	−58.3	0.0	0.0	0.0	0.0	0.0	−126	68.0	0.0
	49.0	18.8	293	−10.8	−9.0	57.8	61.9	33.0	15.0	−126	84.0	−21.9
	0.7	3.0	−1.3	1.0	1.4	6.4	10.5	0.0	1.4	3.3	1.8	2.0
	6.8	4.9	30.5	0.1	0.1	−1.6	−6.5	2.5	4.3	0.1	−1.8	0.6
	7.5	7.9	29.1	1.1	1.5	4.8	4.0	2.5	5.7	3.4	−0.0	2.6
	41.5	10.9	264	−11.9	−10.5	53.0	57.9	30.5	9.3	−129	84.0	−24.5
	41.5	10.9	264	−11.9	−10.5	53.0	57.9	30.5	9.3	−129	84.0	−24.5
	−3.1	9.2	−2.1	1.9	3.1	−6.3	1.9	−2.8	0.3	−0.7	−1.6	−0.6
	38.4	20.1	262	−10.0	−7.4	46.7	59.7	27.7	9.5	−130	82.4	−25.1
	—	10.9	264	−11.9	−10.5	53.0	—	—	9.3	−129	—	−24.5
Per share
	₹6.61	₹1.55	₹37.54	−₹1.69	−₹1.49	₹7.52	₹8.22	₹4.34	₹1.31	−₹18.37	₹11.93	−₹3.48
	₹6.61	₹1.55	₹37.47	−₹1.69	−₹1.49	₹7.50	₹8.19	₹4.32	₹1.31	−₹18.36	₹11.92	−₹3.48
Other comprehensive income — detail
	−3.1	9.2	−2.1	1.9	3.1	−6.3	—	—	—	—	—	—
	0.3	3.5	0.6	1.1	4.9	1.1	0.0	−0.1	0.4	0.7	0.3	−1.1
	0.1	0.9	1.7	0.0	0.0	0.0	—	—	—	—	—	—
	−3.3	6.5	−1.0	0.7	−1.8	−7.3	1.9	−2.7	−0.2	−1.4	−1.9	0.5
	—	—	—	—	—	—	—	—	9.3	−129	—	−24.5
Per share — as-filed variants
	₹6.61	₹1.55	₹37.54	−₹1.69	−₹1.49	₹7.52	₹8.22	₹4.34	₹1.31	−₹18.37	₹11.93	−₹3.48
	₹6.61	₹1.55	₹37.47	−₹1.69	−₹1.49	₹7.50	₹8.19	₹4.32	₹1.31	−₹18.36	₹11.92	−₹3.48
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	344	307	284	309	282	323	342	288	286	265	268	253
	54.4%	53.4%	54.5%	53.3%	53.5%	54.9%	64.1%	62.2%	64.0%	61.3%	61.7%	60.8%
Adjusted (ex-exceptional items) — derived
	49.0	31.2	17.9	47.4	−9.0	57.8	61.9	33.0	15.0	−0.2	16.0	−21.9
	0.0	−12.4	276	−58.3	0.0	0.0	0.0	0.0	0.0	−126	68.0	0.0
	41.5	18.1	16.1	46.4	−10.5	53.0	57.9	30.5	9.3	−3.7	16.0	−24.5
	₹6.61	₹2.57	₹2.29	₹6.59	−₹1.49	₹7.52	₹8.22	₹4.34	₹1.31	−₹0.52	₹2.27	−₹3.48

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

UNICHEMLAB₹488.80

Unichem Laboratories Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersGUFICBIO RPGLIFE GUJTHEM SMSPHARMA ORCHPHARMA INDSWFTLAB SOLARA FDCMcap ₹3,441 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	415.6	434.4	431.7	446.4	462.2	533.1	587.2	526.6	579.0	521.2	575.1	632.6
Other Income	5.5	11.3	6.2	3.9	8.8	13.6	9.3	6.8	21.0	11.8	23.5	15.6
Total Income	421.2	445.7	437.9	450.3	471.0	546.7	596.4	533.4	599.9	533.0	598.6	648.2
Expenses
+ Cost of Materials Consumed	174.9	193.9	197.7	208.1	210.3	175.1	275.3	217.5	193.1	174.3	184.0	190.0
+ Purchases of Stock-in-Trade	0.2	0.2	0.2	0.3	15.2	63.4	33.5	51.0	39.8	48.9	91.8	67.3
+ Changes in Inventories	-12.4	-27.6	-31.0	-47.8	-51.0	-47.0	-44.2	-23.4	37.6	13.9	-7.8	31.3
+ Employee Benefit Expense	96.7	98.1	99.4	98.5	98.8	101.7	96.5	107.4	100.1	99.3	92.9	103.3
+ Finance Costs	6.7	5.6	4.6	4.0	4.8	6.8	5.5	6.5	8.2	7.4	9.4	6.6
+ Depreciation & Amortisation	29.5	27.9	27.2	28.3	28.5	30.5	29.7	31.8	31.5	31.3	30.6	29.9
+ Other Expenses	147.3	131.7	140.0	143.9	131.3	154.3	142.4	151.6	142.3	140.0	166.6	170.8
Total Expenses	443.0	429.7	438.1	435.3	438.0	484.9	538.6	542.4	552.5	515.1	567.4	599.2
EBITDA	8.8	38.1	25.4	43.5	57.5	85.5	83.7	22.5	66.2	44.8	47.7	69.9
EBIT	-20.7	10.3	-1.8	15.2	29.0	55.0	54.0	-9.3	34.7	13.5	17.1	40.0
Profit
PBT before Exceptional Items	-21.9	16.0	-0.2	15.0	33.0	61.9	57.8	-9.0	47.4	17.9	31.2	49.0
+ Exceptional Items	0.0	68.0	-125.6	0.0	0.0	0.0	0.0	0.0	-58.3	275.5	-12.4	0.0
Pretax Income	-21.9	84.0	-125.9	15.0	33.0	61.9	57.8	-9.0	-10.8	293.4	18.8	49.0
+ Current Tax	2.0	1.8	3.3	1.4	0.0	10.5	6.4	1.4	1.0	-1.3	3.0	0.7
+ Deferred Tax	0.6	-1.8	0.1	4.3	2.5	-6.5	-1.6	0.1	0.1	30.5	4.9	6.8
Tax Expense	2.6	-0.0	3.4	5.7	2.5	4.0	4.8	1.5	1.1	29.1	7.9	7.5
Net Income	-24.5	84.0	-129.3	9.3	30.5	57.9	53.0	-10.5	-11.9	264.3	10.9	41.5
+ Net Income — Continuing Ops	-24.5	84.0	-129.3	9.3	30.5	57.9	53.0	-10.5	-11.9	264.3	10.9	41.5
+ Other Comprehensive Income	-0.6	-1.6	-0.7	0.3	-2.8	1.9	-6.3	3.1	1.9	-2.1	9.2	-3.1
Total Comprehensive Income	-25.1	82.4	-130.0	9.5	27.7	59.7	46.7	-7.4	-10.0	262.2	20.1	38.4
Net Income to Common	-24.5	—	-129.3	9.3	—	—	53.0	-10.5	-11.9	264.3	10.9	—
Per Share
Basic EPS	-3.48	11.93	-18.37	1.31	4.34	8.22	7.52	-1.49	-1.69	37.54	1.55	6.61
Diluted EPS	-3.48	11.92	-18.36	1.31	4.32	8.19	7.50	-1.49	-1.69	37.47	1.55	6.61
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-6.3	3.1	1.9	-2.1	9.2	-3.1
+ Items NOT to be Reclassified to P&L	-1.1	0.3	0.7	0.4	-0.1	0.0	1.1	4.9	1.1	0.6	3.5	0.3
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.0	0.0	0.0	1.7	0.9	0.1
+ Items to be Reclassified to P&L	0.5	-1.9	-1.4	-0.2	-2.7	1.9	-7.3	-1.8	0.7	-1.0	6.5	-3.3
Comprehensive Income — Owners of Parent	-24.5	—	-129.3	9.3	—	—	—	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	-3.48	11.93	-18.37	1.31	4.34	8.22	7.52	-1.49	-1.69	37.54	1.55	6.61
Diluted EPS — Continuing Operations	-3.48	11.92	-18.36	1.31	4.32	8.19	7.50	-1.49	-1.69	37.47	1.55	6.61
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	252.8	267.9	264.8	285.9	287.7	341.6	322.6	281.6	308.6	284.1	307.1	344.0
Gross Margin %	60.83	61.67	61.34	64.03	62.25	64.07	54.94	53.47	53.30	54.51	53.40	54.38
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-21.9	16.0	-0.2	15.0	33.0	61.9	57.8	-9.0	47.4	17.9	31.2	49.0
− Exceptional Items (reconciliation)	0.0	68.0	-125.6	0.0	0.0	0.0	0.0	0.0	-58.3	275.5	-12.4	0.0
Net Income Adj (tax-effected)	-24.5	16.0	-3.7	9.3	30.5	57.9	53.0	-10.5	46.4	16.1	18.1	41.5
EPS Adj	-3.48	2.27	-0.52	1.31	4.34	8.22	7.52	-1.49	6.59	2.29	2.57	6.61
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	14.1	14.1	14.1	14.1	14.1	14.1	14.1	14.1	14.1	14.1	14.1	14.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Unichem Laboratories Q2 FY27 results date

Unichem Laboratories (NSE: UNICHEMLAB) will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, according to the board-meeting notice it filed on 21 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹41.5 crore, against a loss of ₹10.5 crore in Q1 FY26 and up 280.1% from ₹10.9 crore in Q4 FY26. Revenue from operations was ₹633 crore, up 20.1% year on year and up 10.0% from the previous quarter.

Board-meeting notice filed: 21 October 2026
Q2 FY26 results (a year earlier): 11 November 2025
Q1 FY27 results (the latest): 11 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 4 November 2026Wednesday · notice filed 21 Oct
Q1 FY27 net profit: ₹41.5 Crloss ₹10.5 Cr in Q1 FY26+280.1% vs Q4 FY26
Q1 FY27 revenue: ₹633 Cr+20.1% vs Q1 FY26+10.0% vs Q4 FY26
Q1 FY27 operating margin: 6.3%+8.1 pts vs Q1 FY26+3.4 pts vs Q4 FY26
Q2 FY26 net loss (a year earlier): −₹11.9 CrRevenue ₹579 Cr
Q1 FY27 EPS (basic): ₹6.61

Questions

When will Unichem Laboratories announce its Q2 FY27 results?

On 4 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 21 October 2026). Last year it reported Q2 FY26 on 11 November 2025.

What was Unichem Laboratories' net profit in FY26?

Consolidated net profit was ₹253 crore in FY26 (April 2025–March 2026), up 83.9% from ₹138 crore in FY25. It was a loss of ₹70.5 crore in FY24 and a loss of ₹202 crore in FY23.

What was Unichem Laboratories' revenue in FY26?

Revenue from operations was ₹2,202 crore in FY26 (April 2025–March 2026), up 4.3% from ₹2,111 crore in FY25. It was ₹1,705 crore in FY24 and ₹1,343 crore in FY23: up 63.9% over three years, 17.9% a year on average.

What will Unichem Laboratories' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net loss was ₹11.9 crore and revenue from operations ₹579 crore. The latest quarter, Q1 FY27, had a net profit of ₹41.5 crore and revenue of ₹633 crore.

What were Unichem Laboratories' Q1 FY27 results?

Consolidated net profit was ₹41.5 crore, against a loss of ₹10.5 crore in Q1 FY26 and up 280.1% from ₹10.9 crore in Q4 FY26. Revenue from operations was ₹633 crore, up 20.1% year on year and up 10.0% from the previous quarter.

How has Unichem Laboratories' profit changed over the last four quarters?

Net profit by quarter: a loss of ₹11.9 crore in Q2 FY26, a profit of ₹264 crore in Q3 FY26, a profit of ₹10.9 crore in Q4 FY26 and a profit of ₹41.5 crore in Q1 FY27. That is a combined profit of ₹305 crore over the four quarters, up 132.9% from ₹131 crore in the four quarters before. Revenue from operations: ₹579 crore, ₹521 crore, ₹575 crore and ₹633 crore.

Where do these Unichem Laboratories figures come from?

From Unichem Laboratories' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.